文献速递糖尿病

弱势社区1型糖尿病患者技术使用与内分泌诊疗障碍

Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2021-05-17

研究通过佛罗里达和加州16个焦点小组(86名成人1型糖尿病患者)探讨弱势社区使用糖尿病技术和内分泌诊疗的障碍。按频率依次为提供者层面(负面就诊经历)、系统层面(经济覆盖)和个体层面(偏好)。超50%参与者过去一年未看内分泌科医生或仅就诊一次;佛州技术使用率低于加州,且泵使用与SES/种族相关,CGM使用与种族/教育程度相关。

要点

  • 障碍按频率为提供者负面经历、经济覆盖、个人偏好。
  • 超50%参与者过去一年未看或仅看一次内分泌科。
  • 佛州CGM使用38%、泵43%,加州CGM 63%、泵69%。

核心结论

  • 弱势社区1型糖尿病患者在技术和内分泌诊疗方面存在多层障碍,需多层面干预。

研究设计与样本

  • 在佛罗里达和加州开展16个焦点小组,共86名≥18岁1型糖尿病成人,入选标准包括DKA住院、HbA1c>9%和/或在联邦合格健康中心接受护理。

主要发现

  • 障碍按频率依次为提供者层面(负面就诊经历)、系统层面(经济覆盖)和个体层面(偏好)。
  • 超过50%参与者过去一年未看内分泌科医生或仅就诊一次(包括住院期间)。
  • 佛州CGM使用38%、泵使用43%;加州CGM使用63%、泵使用69%。
  • 佛州泵使用与SES(P=0.02)和种族/ ethnicity(P=0.01)显著相关;加州CGM使用与种族/ethnicity(P=0.05)和教育水平(P=0.02)显著相关。

临床怎么用

  • 内分泌科医生应关注弱势社区1型糖尿病患者的提供者负面经历、经济覆盖和个体偏好障碍。
  • 针对SES、种族/ethnicity和教育水平差异,考虑多层面干预以减少技术和诊疗 disparities。

局限性

  • 研究仅纳入佛罗里达和加州特定入选标准的成人,结果可能不适用于其他地区或人群。
  • 焦点小组定性设计可能受参与者自我报告偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Disparities in type 1 diabetes related to use of technologies like continuous glucose monitors (CGMs) and utilization of diabetes care are pronounced based on socioeconomic status (SES), race, and ethnicity. However, systematic reports of perspectives from patients in vulnerable communities regarding barriers are limited. RESEARCH DESIGN AND METHODS: To better understand barriers, focus groups were conducted in Florida and California with adults ≥18 years old with type 1 diabetes with selection criteria including hospitalization for diabetic ketoacidosis, HbA1c >9%, and/or receiving care at a Federally Qualified Health Center. Sixteen focus groups were conducted in English or Spanish with 86 adults (mean age 42 ± 16.2 years). Transcript themes and pre-focus group demographic survey data were analyzed. In order of frequency, barriers to diabetes technology and endocrinology care included 1) provider level (negative provider encounters), 2) system level (financial coverage), and 3) individual level (preferences). RESULTS: Over 50% of participants had not seen an endocrinologist in the past year or were only seen once including during hospital visits. In Florida, there was less technology use overall (38% used CGMs in FL and 63% in CA; 43% used pumps in FL and 69% in CA) and significant differences in pump use by SES (P = 0.02 in FL; P = 0.08 in CA) and race/ethnicity (P = 0.01 in FL; P = 0.80 in CA). In California, there were significant differences in CGM use by race/ethnicity (P = 0.05 in CA; P = 0.56 in FL) and education level (P = 0.02 in CA; P = 0.90 in FL). CONCLUSIONS: These findings provide novel insights into the experiences of vulnerable communities and demonstrate the need for multilevel interventions aimed at offsetting disparities in diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Walker AF, Hood KK, Gurka MJ, et al. Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes Care. 2021. PMID: 34001535. doi:10.2337/dc20-2753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。